Literature DB >> 23205295

Breast cancer manifested by hematologic disorders.

Takashi Ishikawa1, Daisuke Shimizu, Ayako Kito, Ikuko Ota, Takeshi Sasaki, Mikiko Tanabe, Akimitsu Yamada, Hitoshi Arioka, Satoru Shimizu, Junichi Wakasugi, Ryutaro Mori, Takashi Chishima, Yasushi Ichikawa, Itaru Endo.   

Abstract

Breast cancer is the most common type of cancer in women. However, it is very rarely manifested as hematologic disorders. A 35-year-old woman was admitted because of disseminated intravascular coagulation. Examinations revealed the presence of breast cancer in her left breast; therefore, paclitaxel was administered weekly. Although disseminated intravascular coagulation was controlled, pulmonary dysfunction due to lymphangitis carcinomatosa suddenly occurred 10 weeks after treatment. Pulmonary dysfunction was effectively treated with epirubicin and cyclophosphamide. Twenty-three weeks after treatment, the patient developed liver dysfunction accompanied with jaundice due to progressive metastatic lesions in the liver; liver dysfunction improved after the administration of vinorelbine. Subsequently, because of the recurrence of pulmonary dysfunction, rechallenge with epirubicin and cyclophosphamide was performed and was effective; however, this therapy was discontinued because of its adverse effects. She expired of liver failure 33 weeks after the occurrence of disseminated intravascular coagulation. Metastatic tumors in the bone marrow, lung, and liver showed different sensitivities to different anti-cancer agents. We report a case of breast cancer manifested by hematologic disorders which was treated by a sequential chemotherapy.

Entities:  

Keywords:  Breast cancer; disseminated intravascular coagulation; multiple organ metastases

Year:  2012        PMID: 23205295      PMCID: PMC3506789          DOI: 10.3978/j.issn.2072-1439.2012.10.17

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  9 in total

1.  Thrombotic thrombocytopenic purpura in metastatic carcinoma of the breast.

Authors:  N von Bubnoff; M Sandherr; F Schneller; C Peschel
Journal:  Am J Clin Oncol       Date:  2000-02       Impact factor: 2.339

2.  Diffuse bone metastasis with hematologic disorders from gastric cancer: clinicopathological features and prognosis.

Authors:  T Etoh; H Baba; A Taketomi; H Nakashima; S Kohnoe; Y Seo; T Fukuda; H Tomoda
Journal:  Oncol Rep       Date:  1999 May-Jun       Impact factor: 3.906

3.  Disseminated intravascular coagulation in solid tumors: clinical and pathologic study.

Authors:  S Sallah; J Y Wan; N P Nguyen; L R Hanrahan; G Sigounas
Journal:  Thromb Haemost       Date:  2001-09       Impact factor: 5.249

4.  Thrombotic thrombocytopenic purpura associated with bone marrow metastasis and secondary myelofibrosis in cancer.

Authors:  Jae C Chang; Tahir Naqvi
Journal:  Oncologist       Date:  2003

5.  Microangiopathic hemolytic anemia, thrombocytopenia, and renal failure in patients treated for adenocarcinoma.

Authors:  B R Kressel; K P Ryan; A T Duong; J Berenberg; P S Schein
Journal:  Cancer       Date:  1981-10-15       Impact factor: 6.860

Review 6.  The basics of epithelial-mesenchymal transition.

Authors:  Raghu Kalluri; Robert A Weinberg
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

7.  High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.

Authors:  Sven Rottenberg; Janneke E Jaspers; Ariena Kersbergen; Eline van der Burg; Anders O H Nygren; Serge A L Zander; Patrick W B Derksen; Michiel de Bruin; John Zevenhoven; Alan Lau; Robert Boulter; Aaron Cranston; Mark J O'Connor; Niall M B Martin; Piet Borst; Jos Jonkers
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-29       Impact factor: 11.205

8.  Breast cancer with an unusual leukemia-like presentation: case report and literature review.

Authors:  Yuan-Hsin Chang; Ruey-Kuen Hsieh; Ming-Chi Chang; Gon-Shen Chen
Journal:  Med Oncol       Date:  2007-07-28       Impact factor: 3.064

9.  Skeletal metastases.

Authors:  C S Galasko
Journal:  Clin Orthop Relat Res       Date:  1986-09       Impact factor: 4.176

  9 in total
  11 in total

1.  Value of pre-treatment biomarkers in prediction of response to neoadjuvant endocrine therapy for hormone receptor-positive postmenopausal breast cancer.

Authors:  Min Ying; Yingjian He; Meng Qi; Bin Dong; Aiping Lu; Jinfeng Li; Yuntao Xie; Tianfeng Wang; Benyao Lin; Tao Ouyang
Journal:  Chin J Cancer Res       Date:  2013-08       Impact factor: 5.087

2.  Expression and regulatory function of miRNA-182 in triple-negative breast cancer cells through its targeting of profilin 1.

Authors:  Hailing Liu; Yan Wang; Xin Li; Yan-jun Zhang; Jie Li; Yi-qiong Zheng; Mei Liu; Xin Song; Xi-ru Li
Journal:  Tumour Biol       Date:  2013-02-22

3.  Optimization of apparent diffusion coefficient measured by diffusion-weighted MRI for diagnosis of breast lesions presenting as mass and non-mass-like enhancement.

Authors:  Liuquan Cheng; Yuhan Bai; Jing Zhang; Mei Liu; Xiru Li; Ailiang Zhang; Xiaojing Zhang; Lin Ma
Journal:  Tumour Biol       Date:  2013-02-10

4.  Effects of ARHI on breast cancer cell biological behavior regulated by microRNA-221.

Authors:  Ying Li; Mei Liu; Yanjun Zhang; Chun Han; Junhao You; Junlan Yang; Cheng Cao; Shunchang Jiao
Journal:  Tumour Biol       Date:  2013-06-26

5.  Clinical pathological characteristics and prognostic analysis of diabetic women with luminal subtype breast cancer.

Authors:  Yuanting Xiao; Sheng Zhang; Guofang Hou; Xiaobei Zhang; Xiaomeng Hao; Jin Zhang
Journal:  Tumour Biol       Date:  2013-10-05

6.  QM-FISH analysis of the genes involved in the G1/S checkpoint signaling pathway in triple-negative breast cancer.

Authors:  Sheng Zhang; Yingbo Shao; Guofang Hou; Jingchao Bai; Weiping Yuan; Linping Hu; Tao Cheng; Anders Zetterberg; Jin Zhang
Journal:  Tumour Biol       Date:  2013-10-05

7.  Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer.

Authors:  Li Bian; Tao Wang; Shaohua Zhang; Zefei Jiang
Journal:  Tumour Biol       Date:  2013-06-01

8.  PARP inhibitor reduces proliferation and increases apoptosis in breast cancer cells.

Authors:  Yan Shi; Fang Zhou; Feng Jiang; Hong Lu; Jianjun Wang; Chuanyao Cheng
Journal:  Chin J Cancer Res       Date:  2014-04       Impact factor: 5.087

9.  Nemo-like kinase associated with proliferation and apoptosis by c-Myb degradation in breast cancer.

Authors:  Yeqing Huang; Ying Jiang; Weiqi Lu; Yong Zhang
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

10.  Foxo3a expression is a prognostic marker in breast cancer.

Authors:  Ying Jiang; Lin Zou; Wei-Qi Lu; Yong Zhang; Ai-Guo Shen
Journal:  PLoS One       Date:  2013-08-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.